AVEO PHARMACEUTICALS INC's ticker is AVEO and the CUSIP is 053588109. A total of 49 filers reported holding AVEO PHARMACEUTICALS INC in Q1 2017. The put-call ratio across all filers is - and the average weighting 2.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $23,000 | -95.2% | 37,000 | -77.5% | 0.00% | -90.0% |
Q1 2018 | $476,000 | -36.4% | 164,300 | -38.7% | 0.03% | -25.0% |
Q4 2017 | $748,000 | -48.0% | 268,200 | -31.9% | 0.04% | -48.1% |
Q3 2017 | $1,438,000 | +2719.6% | 394,000 | +311.3% | 0.08% | +1825.0% |
Q4 2016 | $51,000 | -75.4% | 95,800 | -58.8% | 0.00% | -76.5% |
Q3 2016 | $207,000 | -26.3% | 232,657 | -20.5% | 0.02% | -34.6% |
Q2 2016 | $281,000 | +75.6% | 292,800 | +129.5% | 0.03% | +30.0% |
Q4 2015 | $160,000 | -24.2% | 127,600 | +5.1% | 0.02% | -31.0% |
Q2 2015 | $211,000 | -56.1% | 121,400 | -63.7% | 0.03% | -56.7% |
Q1 2015 | $481,000 | +208.3% | 334,100 | +78.3% | 0.07% | +157.7% |
Q4 2014 | $156,000 | +11.4% | 187,400 | +49.9% | 0.03% | +23.8% |
Q3 2014 | $140,000 | +94.4% | 125,000 | +213.3% | 0.02% | +90.9% |
Q2 2014 | $72,000 | +67.4% | 39,900 | +66.9% | 0.01% | +57.1% |
Q4 2013 | $43,000 | – | 23,900 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Greylock XI GP Limited Partnership | 584,004 | $1,068,000 | 100.00% |
GREAT POINT PARTNERS LLC | 2,325,000 | $4,255,000 | 1.89% |
Sarissa Capital Management LP | 2,570,759 | $4,704,000 | 1.60% |
Deer VI & Co. LLC | 675,242 | $1,236,000 | 0.68% |
Palo Alto Investors LP | 1,200,800 | $2,197,000 | 0.16% |
Baupost Group | 3,829,350 | $7,008,000 | 0.11% |
Gruss Capital Management LP | 533,253 | $976,000 | 0.05% |
Granahan Investment Management | 676,451 | $1,238,000 | 0.04% |
Fore Research & Management, LP | 674,200 | $1,233,000 | 0.04% |
TFS CAPITAL LLC | 210,369 | $385,000 | 0.03% |